- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Optimizing Bispecific Use in Multiple Myeloma Treatment
A key opinion leader explores the integration of bispecifics into MM therapy regimens.
EP: 1.Unmet Needs and Treatment Approaches in Newly Diagnosed Multiple Myeloma
EP: 2.ASH 2023: PERSEUS Trial Overview
EP: 3.Considerations for Combination Therapy and MRD Testing in Newly Diagnosed Multiple Myeloma Patients
EP: 4.ASH 2023: Analyzing IsKia Trial
EP: 5.Examining Data from MonumenTAL-2 Study
EP: 6.Optimizing Bispecific Use in Multiple Myeloma Treatment
EP: 7.Navigating Impact of RRMM Treatment on Patient Quality of Life
EP: 8.Key RRMM-Related Takeaways from ASH 2023
This is a video synopsis/summary of a Post Conference Perspectives featuring Rafael Fonseca, MD.
When using bispecific antibodies in multiple myeloma (MM), proper sequencing with chimeric antigen receptor (CAR) T-cell therapy is important since they can target similar antigens. CAR T-cell therapy may be favored earlier given the one-and-done appeal and quality of life benefits shown in studies like CARTITUDE-4 and KarMMa. Bispecifics are now better managed with less concern about cytokine release syndrome, even allowing outpatient administration at some centers, potentially expanding community hospital access beyond academic sites.
While bispecifics don’t match CAR T-cell therapy response rates, their wider eligibility makes them an exciting option. They will also likely expand into solid tumors. However, infections remain a key long-term toxicity that requires prevention/proactive management with IgG replacement and antibiotics. Understanding optimal dosing and schedules for antibodies like talquetamab will also minimize cumulative toxicities like rash and weight loss that can impact quality of life. But with proper mitigation strategies, bispecifics have a promising future in myeloma.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Lp(a) and Getting a Head Start Against Heart Disease: Jeremy Wigginton, MD
April 8th 2025Lipoprotein a (Lp[a]) is a valuable tool for assessing a patient's risk of cardiovascular disease, which can facilitate earlier intervention efforts and reduce health care costs, argued Jeremy Wigginton, MD.
Read More
Worse CTD-PAH Prognosis Seen With Higher HFA-PEFF Score
April 8th 2025The findings from this single-center retrospective study compare outcomes between 2 groups of patients living with connective tissue disease–associated pulmonary arterial hypertension (CTD-PAH) stratified by their Heart Failure Association–preserved ejection fraction (HFA-PEFF) algorithm score.
Read More
Guselkumab Shows Sustained Efficacy in Phase 3b APEX Study for Active PsA
April 8th 2025Long-term extension analysis of the phase 3b APEX study (NCT04882098) through 3 years of treatment will further assess the sustained efficacy of guselkumab (Tremfya; Johnson & Johnson) in limiting structural damage in patients with active psoriatic arthritis (PsA).
Read More
